Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexlansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.60 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.60 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.60 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.60 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.60 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.60 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.60 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lansoprazole SCHEMBL28026811 | 1.00 | NPC1 (0.62) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1274164 | 1.00 | NPC1 (0.62) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29353881 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29353345 | 0.99 | CYP2C9 (0.63) | NPC1RAB9ACYP2C9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809542-B2 | Salts of benzimidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-19 | — | — | US | claimed |
| US-20130281704-A1 | SALTS OF BENZIMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-10-24 | — | — | US | claimed |
| US-7339064-B2 | (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2 -pyridinyl)methyl)sulfinyl)-1H-benzimidazole, (R(+)-lansoprazole); antiulcer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-04 | — | — | US | claimed |
| US-20050228026-A1 | (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2 -pyridinyl)methyl)sulfinyl)-1H-benzimidazole, (R(+)-lansoprazole); antiulcer agent | FUJISHIMA AKIRA | 2005-10-13 | — | — | US | claimed |
| US-8809542-B2 | Salts of benzimidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20130281704-A1 | SALTS OF BENZIMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2573082-A1 | CRYSTALLINE SOLVATED FORMS OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE | Takeda Pharmaceutical Company Limited (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2292612-A2 | Crystalline solvated forms of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole | Takeda Pharmaceutical Company Limited (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100286400-A1 | CRYSTALLINE SOLVATED FORMS OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2227462-A1 | CRYSTALLINE SOLVATED FORMS OF (R) -2- [[[3-METHYL-4- (2, 2, 2-TRIFLUOROETHOXY) -2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZ IMIDAZOLE | Takeda Pharmaceutical Company Limited (JP) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009088857-A1 | CRYSTALLINE SOLVATED FORMS OF (R) -2- [ [ [3-METHYL-4- (2, 2, 2-TRIFLUOROETHOXY) -2-PYRIDINYL] METHYL] SULFINYL] -1H-BENZ IMIDAZOLE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | WO | disclosed |
| US-20070254924-A1 | Salts of benzimidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-7271182-B2 | Salts of benzimidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1306375-B1 | SALTS OF BENZIMIDAZOLE COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-20030181487-A1 | Salts of benzimidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1306375-A1 | SALTS OF BENZIMIDAZOLE COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |